Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoca-cola Euro. Regulatory News (CCEP)

Share Price Information for Coca-cola Euro. (CCEP)

Share Price is delayed by 15 minutes
Get Live Data
7,435.00    50.00 (0.68%)
Bid:
7,415.00
Ask:
7,425.00
Spread: 10.00 (0.135%)
Market Cap: £32.92b
CCEP Live PriceLast checked at - London Stock Exchange

Intraday Coca-cola Euro. Share Chart

Update statement on 2025 AGM voting results

21 Nov 2025 15:00

RNS Number : 5865I
Coca-Cola Europacific Partners plc
21 November 2025
 

21 November 2025

Coca-Cola Europacific Partners plc

("the Company")

Update statement on 2025 Annual General Meeting voting results

At the Company's 2025 Annual General Meeting ("AGM") held on 22 May 2025, all resolutions were successfully passed with the requisite majority of votes. However, in respect of resolution 24 ("Rule 9 Waiver Resolution"), we acknowledge that a number of our shareholders did not support the resolution (of votes cast, 74.95% voted in favour).

The Rule 9 Waiver Resolution related to the approval by independent shareholders of a waiver obtained from the Panel on Takeovers and Mergers in respect of an obligation that could arise on Olive Partners, S.A. ("Olive"), or any persons acting in concert with Olive, to make a general offer for all the issued ordinary share capital of the Company following any increase in the percentage of shares held by Olive, or any persons acting in concert with Olive, resulting from the exercise by the Company of the authority to purchase its own shares pursuant to resolutions 27 and 28 (which received approval from 99.22% and 98.22% of those voting respectively).

The Board believes that it is in the best interests of shareholders that the Company has the flexibility to return value to shareholders through future buyback programmes as demonstrated in our commitment to return up to €1bn to shareholders as part of the share buyback programme announced on 14 February 2025. If the Rule 9 Waiver Resolution had not been approved, the Company would not have been able to effect such buyback programmes as explained in the 2025 Notice of AGM and also in the Letter to Shareholders issued via RNS on 12 May 2025.

Since the AGM, the Company has continued to engage where appropriate with its shareholders on the rationale and merits of the Rule 9 Waiver Resolution, and to address any concerns they may have. The Board believes that share buybacks represent an attractive means of returning capital to shareholders and, as such, they form a core component of the Company's capital allocation framework. The Board recognises, and acknowledges, shareholder concerns around the use of Rule 9 waivers in the context of share buybacks and continues to evaluate other means of returning capital to shareholders. The Board is grateful for the engagement of shareholders.  

CONTACTS

Company Secretariat

Clare Wardle

T +44 20 7355 8406

Investor Relations

Sarah Willett

T +44 7970 145 218

Media Relations

Shanna Wendt

T +44 7976 595 168

 

ABOUT CCEP

Coca-Cola Europacific Partners is one of the world's leading consumer goods companies. We make, move and sell some of the world's most loved brands - serving nearly 600 million consumers and helping over 4 million customers across 31 countries grow.

We combine the strength and scale of a large, multi-national business with an expert, local knowledge of the customers we serve and communities we support.

The Company is currently listed on Euronext Amsterdam, NASDAQ, London Stock Exchange and on the Spanish Stock Exchanges, and a constituent of both the Nasdaq 100 and FTSE 100 indices, trading under the symbol CCEP (ISIN No. GB00BDCPN049).

For more information about CCEP, please visit www.cocacolaep.com & follow CCEP on LinkedIn

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMEADFFAEFSFFA
Date   Source Headline
12th Jun 20264:30 pmRNSDirector/PDMR Shareholding
5th Jun 20263:30 pmRNSDirector/PDMR Shareholding
3rd Jun 202612:30 pmRNSDirector/PDMR Shareholding
1st Jun 20261:30 pmRNSTotal Voting Rights
29th May 20261:00 pmRNSResult of AGM
21st May 20263:30 pmRNSDirector/PDMR Shareholding
18th May 202611:00 amRNSLetter to Shareholders
1st May 20264:15 pmRNSDirector/PDMR Shareholding
1st May 20261:30 pmRNSTotal Voting Rights
28th Apr 20267:00 amRNSQ1 Trading Update & Interim Dividend Declaration
27th Apr 20263:00 pmRNSTransactions in Own Shares
22nd Apr 20262:15 pmRNSDirector/PDMR Shareholding
20th Apr 20261:30 pmRNSTransactions in Own Shares
16th Apr 20269:15 amRNSNotice of AGM
15th Apr 202610:30 amRNSDirector/PDMR Shareholding
13th Apr 202612:30 pmRNSTransaction in Own Shares
10th Apr 202611:00 amRNSSID Appointment and Board Committee Changes
7th Apr 20262:00 pmRNSTransaction in Own Shares
1st Apr 20262:30 pmRNSTotal Voting Rights
1st Apr 202611:00 amRNSChange of Company Secretary
30th Mar 20263:30 pmRNSTransactions in Own Shares
27th Mar 20269:00 amRNSDirector/PDMR Shareholding
24th Mar 202612:00 pmRNSDirector/PDMR Shareholding
23rd Mar 20267:00 amRNSTransactions in Own Shares
20th Mar 20264:45 pmRNSDirector/PDMR Shareholding
20th Mar 20267:00 amRNSTransactions in Own Shares
19th Mar 20267:00 amRNSTransactions in Own Shares
18th Mar 20267:00 amRNSTransactions in Own Shares
17th Mar 20267:00 amRNSTransactions in Own Shares
17th Mar 20267:00 amRNSTransactions in Own Shares
16th Mar 20265:00 pmRNSDirector/PDMR Shareholding
16th Mar 20267:00 amRNSTransactions in Own Shares
16th Mar 20267:00 amRNSTransactions in Own Shares
13th Mar 202612:11 pmRNSAnnual Financial Report
13th Mar 202612:11 pmRNSAnnual Financial Report
13th Mar 20267:00 amRNSTransactions in Own Shares
13th Mar 20267:00 amRNSTransactions in Own Shares
12th Mar 20267:00 amRNSTransactions in Own Shares
12th Mar 20267:00 amRNSTransactions in Own Shares
11th Mar 20267:00 amRNSTransactions in Own Shares
10th Mar 20267:00 amRNSTransactions in Own Shares
9th Mar 20267:00 amRNSTransactions in Own Shares
6th Mar 20267:00 amRNSTransactions in Own Shares
5th Mar 20267:00 amRNSTransactions in Own Shares
4th Mar 20264:00 pmRNSDirectorate change
4th Mar 20267:00 amRNSTransactions in Own Shares
3rd Mar 20265:13 pmRNSDirector/PDMR Shareholding
3rd Mar 20265:00 pmRNSHolding(s) in Company
3rd Mar 20267:00 amRNSTransactions in Own Shares
2nd Mar 20261:15 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.